Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.33 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12430504 | 0.89 | L3MBTL1 (0.40) | CYP2A6DRD2DRD3TRPV1SRD5A1 | |
| SCHEMBL8061942 | 0.84 | CYP2A6 (0.52) | CYP2A6DRD2DRD3SRD5A1CYP1A2 | |
| SCHEMBL11430501 | 0.83 | CYP1A2 (0.52) | CYP2A6DRD2DRD3SRD5A1CYP1A2 | |
| SCHEMBL30406729 | 0.83 | CYP1A2 (0.52) | CYP2A6DRD2DRD3SRD5A1CYP1A2 | |
| SCHEMBL20123631 | 0.79 | CYP2A6 (0.45) | CYP2A6DRD2DRD3SRD5A1CYP1A2 | |
| SCHEMBL24011796 | 0.78 | — | — | |
| SCHEMBL30042165 | 0.78 | — | — | |
| SCHEMBL5535806 | 0.78 | CYP2A6 (0.54) | CYP2A6TRPV1CYP1A2L3MBTL1CES1 | |
| Ammonia Solution, Strong SCHEMBL3977602 | 0.76 | DRD2 (0.52) | DRD2DRD3SRD5A1ADRA2AL3MBTL1 | |
| SCHEMBL206466 | 0.76 | CYP2A6 (0.52) | CYP2A6TRPV1CYP1A2CES1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | NEW YORK UNIVERSITY (US) | 2025-01-28 | — | — | US | disclosed |
| EP-3883932-B1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | UNIV NEW YORK (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-4019485-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | Mochida Pharmaceutical Co., Ltd. (JP) | 2022-06-29 | — | — | EP | disclosed |
| US-20220009898-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-01-13 | — | — | US | disclosed |
| US-20220009935-A1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | NEW YORK UNIVERSITY | 2022-01-13 | — | — | US | disclosed |
| US-20220009935-A1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | NEW YORK UNIVERSITY | 2022-01-13 | — | — | US | disclosed |
| EP-2496559-B1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE AND THEIR USE AS HSD 1 INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9663470-B2 | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | VITAE PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160272590-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-09-22 | — | — | US | disclosed |
| US-9353081-B2 | Bicyclic dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-05-31 | — | — | US | disclosed |
| CN-1351601-A | Heterocyclic compounds binding chemotactic factor receptor | ANORMED INC (CA) | 2002-05-29 | — | — | CN | disclosed |
| EP-1163238-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056729-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | disclosed |
| US-5389687-A | Selective antagonists of serotonin | ELI LILLY AND COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
| EP-0343830-B1 | Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes | LILLY CO ELI (US) | 1994-07-13 | — | — | EP | disclosed |
| CN-1024665-C | process for preparing ring-substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes | LILLY CO ELI (US) | 1994-05-25 | — | — | CN | disclosed |
| US-5164385-A | AZETIDINE DERIVATIVES AND HYPOTENSIVE COMPOSITIONS THEREOF | JOHN WYETH & BROTHER, LTD. (GB) | 1992-11-17 | — | — | US | disclosed |
| US-5026707-A | Antiserotonine agents | ELI LILLY AND COMPANY (US) | 1991-06-25 | — | — | US | disclosed |
| CN-1038644-A | Nuclear substituted 2-amino-1,2,3,4-tetralin class | LILLY CO ELI (US) | 1990-01-10 | — | — | CN | disclosed |
| EP-0343830-A2 | Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes | ELI LILLY AND COMPANY (US) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | GLI1, GLI2, SHH | CYP2A6 4734/4885DRD2 4742/4885DRD3 4784/4885 |
| US-20220009898-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | COASY, NAAA, AADAC | CYP2A6 217/4885DRD2 3407/4885DRD3 4109/4885 |
| US-20160272590-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | HSD17B1, HSD3B1, HSD11B1 | CYP2A6 111/4885DRD2 322/4885DRD3 386/4885 |
| US-20220009935-A1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | GLI1, GLI2, SHH | CYP2A6 4734/4885DRD2 4742/4885DRD3 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.